echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Choose more than 50 varieties!

    Choose more than 50 varieties!

    • Last Update: 2021-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Medical Network, April 13 News, April 12, "The "2+4" Alliance of Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps organizes centralized drug procurement and use implementation plan (draft for soliciting comments)" (hereinafter referred to as "soliciting comments" Draft”) was officially announced.
    Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, it united with medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces to form an alliance to carry out centralized drug procurement.
    According to the news at the mobilization and deployment meeting for centralized procurement and use of drugs organized by the autonomous region and the Corps, the "2+4" alliance will select about 50 types of drugs and select 2 to 3 categories of medical consumables.
     
    It is worth noting that the " Notice of Xinjiang Leading Organization Inter-provincial Alliance Drug Centralized Procurement " issued by the Qinghai Provincial Medical Insurance Bureau a few days ago has been circulated in the industry, involving ten varieties, including amoxicillin and clavulanate potassium, aspirin, and C.
    Sodium valerate and other large varieties.
     
    Xinjiang stated that by 2025, it will achieve centralized procurement of more than 500 varieties of medicines at the provincial level (including national and inter-provincial alliances) and more than 5 types of high-value medical consumables.
     
    Increase the proportion of agreed purchases based on the decline
     
    The "Draft for Comments" shows that among the drugs that have never been included in the scope of centralized drug procurement by the national organization, priority will be given to the selection of drugs in the basic medical insurance drug catalog with large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    Purchase with quantity.
    It is divided into two quality levels, the first quality level: original research drugs, reference preparations, generic drugs that have passed the quality and efficacy consistency evaluation of generic drugs, and generic drugs approved by the new registration classification, which are included in the "China Listed Drug Catalogue" Medicines, obtained CGMP, MHRA, FDA, JGMP certifications and exported domestic medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
    At the same time, according to the characteristics of the purchased drugs, the market structure and the competitive situation, the evaluation group will be determined, and the shortlisted companies will be selected according to the methods of negotiation, bargaining and bidding.
    Based on the comprehensive scores of the "Comprehensive Bidding Index System for Drug Purchase with Volume", the companies to be selected are determined.
    The agreed purchase amount shall not be higher than 50% of the agreed purchase amount base, and the agreed purchase amount shall be appropriately increased according to the company's decline.
     
      The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner cannot be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum procurement being implemented by the national provincial procurement platform price.
     
      It is worth noting that in addition to all public medical institutions and military medical institutions in the alliance area, designated chronic disease retail pharmacies in the Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps will also join the mass pharmnet.
    com.
    cn/news/yyzb/" target="_blank">procurement alliance to purchase chronic disease drugs.
    At the same time, we encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
     
      Union accelerate the pace of procurement involving varieties slashed prices
     
      A few days ago, a "Notice of the Qinghai Provincial Medical Security Bureau Office on Filling in Data Related to the Centralized Procurement of Drugs by Xinjiang's Leading Organization of the Inter-provincial Alliance" circulated in the industry, requiring relevant data to be completed before April 12.
     
      According to the information in the form, Qinghai's participation in Xinjiang-led coalition sampling may involve 10 varieties, including: amoxicillin and clavulanate potassium, aspirin, sodium valproate, etc.
    , and there are many large clinical varieties.
     
      According to data from Meinenet, in 2019, the terminal sales of amoxicillin clavulanate potassium in urban public hospitals , county-level public hospitals, urban community centers, and township health centers in China exceeded 6 billion yuan, an increase of 6.
    88% year-on-year.
    Aspirin is the only internal pain reliever with sales of more than 1 billion yuan.
    In recent years, the sales of this product in the terminals of public medical institutions in China have continued to rise, breaking through 2 billion yuan in 2017 and rising to 2.
    4 billion yuan in 2019.
    Aspirin was included in last year's procurement in Shandong Province, and finally selected from the aspirin enteric-coated tablets in Yongning, Jinan.
    Each box of 100 tablets dropped to 0.
    58 yuan, and the price of a single tablet exceeded 6%.
     
      Up to now, together with the "2+4" alliance led by Xinjiang, seven inter-provincial alliances have emerged across the country, namely: the 11 provincial alliances led by Shaanxi; the five provincial alliances led by Chongqing; and the "six provinces and two districts" led by Sichuan Alliance; the 11-province alliance led by Guangdong; the Beijing-Tianjin-Hebei "3+N" alliance, and the "Yangtze River Delta Alliance" that has not yet announced the official procurement documents.
     
      The scale of the alliance's procurement and price reduction cannot be underestimated, and its influence is constantly increasing.
    The first batch of "six provinces and two districts" included 11 varieties in the first batch of inter-provincial alliances.
    The average price of selected drugs fell by 58.
    05%, with the largest decrease of 91.
    69%.
    The prices of many selected injections fell to the floor price.
    A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance has announced the results of the joint procurement of coronary dilatation balloon medical consumables.
    The price of coronary dilatation balloons has dropped from an average price of 3401 yuan to 319 yuan, which is the same as in 2020.
    The average price of the same product of the enterprise is reduced by 90%.
    It is foreseeable that in 2021, Union procurement will bloom all over the country, and the quantity-harvested varieties will usher in a new round of price cuts.
     
      
      (Note: The form is circulated in the industry, and the official release shall prevail)
      Medical Network, April 13 News, April 12, "The "2+4" Alliance of Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps organizes centralized drug procurement and use implementation plan (draft for soliciting comments)" (hereinafter referred to as "soliciting comments" Draft”) was officially announced.
    Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, it united with medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces to form an alliance to carry out centralized drug procurement.
    According to the news at the mobilization and deployment meeting for centralized procurement and use of drugs organized by the autonomous region and the Corps, the "2+4" alliance will select about 50 types of drugs and select 2 to 3 categories of medical consumables.
     
      It is worth noting that the " Notice of Xinjiang Leading Organization Inter-provincial Alliance Drug Centralized Procurement " issued by the Qinghai Provincial Medical Insurance Bureau a few days ago has been circulated in the industry, involving ten varieties, including amoxicillin and clavulanate potassium, aspirin, and C.
    Sodium valerate and other large varieties.
     
      Xinjiang stated that by 2025, it will achieve centralized procurement of more than 500 varieties of medicines at the provincial level (including national and inter-provincial alliances) and more than 5 types of high-value medical consumables.
     
      Increase the proportion of agreed purchases based on the decline
     
      The "Draft for Comments" shows that among the drugs that have never been included in the scope of centralized drug procurement by the national organization, priority will be given to the selection of drugs in the basic medical insurance drug catalog with large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    Purchase with quantity.
    It is divided into two quality levels, the first quality level: original research drugs, reference preparations, generic drugs that have passed the quality and efficacy consistency evaluation of generic drugs, and generic drugs approved by the new registration classification, which are included in the "China Listed Drug Catalogue" Medicines, obtained CGMP, MHRA, FDA, JGMP certifications and exported domestic medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
      At the same time, according to the characteristics of the purchased drugs, the market structure and the competitive situation, the evaluation group will be determined, and the shortlisted companies will be selected according to the methods of negotiation, bargaining and bidding.
    Based on the comprehensive scores of the "Comprehensive Bidding Index System for Drug Purchase with Volume", the companies to be selected are determined.
    The agreed purchase amount shall not be higher than 50% of the agreed purchase amount base, and the agreed purchase amount shall be appropriately increased according to the company's decline.
     
      The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner cannot be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum procurement being implemented by the national provincial procurement platform price.
     
      It is worth noting that in addition to all public medical institutions and military medical institutions in the alliance area, designated chronic disease retail pharmacies in the Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps will also join the mass pharmnet.
    com.
    cn/news/yyzb/" target="_blank">procurement alliance to purchase chronic disease drugs.
    At the same time, we encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
     
      Union accelerate the pace of procurement involving varieties slashed prices
     
      A few days ago, a "Notice of the Qinghai Provincial Medical Security Bureau Office on Filling in Data Related to the Centralized Procurement of Drugs by Xinjiang's Leading Organization of the Inter-provincial Alliance" circulated in the industry, requiring relevant data to be completed before April 12.
     
      According to the information in the form, Qinghai's participation in Xinjiang-led coalition sampling may involve 10 varieties, including: amoxicillin and clavulanate potassium, aspirin, sodium valproate, etc.
    , and there are many large clinical varieties.
     
      According to data from Meinenet, in 2019, the terminal sales of amoxicillin clavulanate potassium in urban public hospitals , county-level public hospitals, urban community centers, and township health centers in China exceeded 6 billion yuan, an increase of 6.
    88% year-on-year.
    Aspirin is the only internal pain reliever with sales of more than 1 billion yuan.
    In recent years, the sales of this product in the terminals of public medical institutions in China have continued to rise, breaking through 2 billion yuan in 2017 and rising to 2.
    4 billion yuan in 2019.
    Aspirin was included in last year's procurement in Shandong Province, and finally selected from the aspirin enteric-coated tablets in Yongning, Jinan.
    Each box of 100 tablets dropped to 0.
    58 yuan, and the price of a single tablet exceeded 6%.
     
      Up to now, together with the "2+4" alliance led by Xinjiang, seven inter-provincial alliances have emerged across the country, namely: the 11 provincial alliances led by Shaanxi; the five provincial alliances led by Chongqing; and the "six provinces and two districts" led by Sichuan Alliance; the 11-province alliance led by Guangdong; the Beijing-Tianjin-Hebei "3+N" alliance, and the "Yangtze River Delta Alliance" that has not yet announced the official procurement documents.
     
      The scale of the alliance's procurement and price reduction cannot be underestimated, and its influence is constantly increasing.
    The first batch of "six provinces and two districts" included 11 varieties in the first batch of inter-provincial alliances.
    The average price of selected drugs fell by 58.
    05%, with the largest decrease of 91.
    69%.
    The prices of many selected injections fell to the floor price.
    A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance has announced the results of the joint procurement of coronary dilatation balloon medical consumables.
    The price of coronary dilatation balloons has dropped from an average price of 3401 yuan to 319 yuan, which is the same as in 2020.
    The average price of the same product of the enterprise is reduced by 90%.
    It is foreseeable that in 2021, Union procurement will bloom all over the country, and the quantity-harvested varieties will usher in a new round of price cuts.
     
      
      (Note: The form is circulated in the industry, and the official release shall prevail)
      Medical Network, April 13 News, April 12, "The "2+4" Alliance of Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps organizes centralized drug procurement and use implementation plan (draft for soliciting comments)" (hereinafter referred to as "soliciting comments" Draft”) was officially announced.
    Initiated by the Xinjiang Uygur Autonomous Region and the Xinjiang Production and Construction Corps, it united with medical institutions in Shaanxi, Gansu, Qinghai, Ningxia and other provinces to form an alliance to carry out centralized drug procurement.
    According to the news at the mobilization and deployment meeting for centralized procurement and use of drugs organized by the autonomous region and the Corps, the "2+4" alliance will select about 50 types of drugs and select 2 to 3 categories of medical consumables.
     
      It is worth noting that the " Notice of Xinjiang Leading Organization Inter-provincial Alliance Drug Centralized Procurement " issued by the Qinghai Provincial Medical Insurance Bureau a few days ago has been circulated in the industry, involving ten varieties, including amoxicillin and clavulanate potassium, aspirin, and C.
    Sodium valerate and other large varieties.
    Medicine, medicine, medicine
     
      Xinjiang stated that by 2025, it will achieve centralized procurement of more than 500 varieties of medicines at the provincial level (including national and inter-provincial alliances) and more than 5 types of high-value medical consumables.
     
      Increase the proportion of agreed purchases based on the decline
      Increase the proportion of agreed purchases based on the decline
     
      The "Draft for Comments" shows that among the drugs that have never been included in the scope of centralized drug procurement by the national organization, priority will be given to the selection of drugs in the basic medical insurance drug catalog with large amounts, high purchase amounts, sufficient competition, and mature clinical use.
    Purchase with quantity.
    It is divided into two quality levels, the first quality level: original research drugs, reference preparations, generic drugs that have passed the quality and efficacy consistency evaluation of generic drugs, and generic drugs approved by the new registration classification, which are included in the "China Listed Drug Catalogue" Medicines, obtained CGMP, MHRA, FDA, JGMP certifications and exported domestic medicines corresponding to the market.
    The second quality level: drugs other than the first quality level.
     
      At the same time, according to the characteristics of the purchased drugs, the market structure and the competitive situation, the evaluation group will be determined, and the shortlisted companies will be selected according to the methods of negotiation, bargaining and bidding.
    Based on the comprehensive scores of the "Comprehensive Bidding Index System for Drug Purchase with Volume", the companies to be selected are determined.
    The agreed purchase amount shall not be higher than 50% of the agreed purchase amount base, and the agreed purchase amount shall be appropriately increased according to the company's decline.
    Enterprise business enterprise
     
      The declared price of drugs that have been purchased in other provinces, cities, or alliance provinces in a centralized manner cannot be higher than the average price of the selected prices, and the declared prices of drugs that have not been purchased in a centralized manner shall not be higher than the minimum procurement being implemented by the national provincial procurement platform price.
     
      It is worth noting that in addition to all public medical institutions and military medical institutions in the alliance area, designated chronic disease retail pharmacies in the Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps will also join the mass pharmnet.
    com.
    cn/news/yyzb/" target="_blank">procurement alliance to purchase chronic disease drugs.
    At the same time, we encourage medical insurance designated social medical institutions and other medical insurance designated retail pharmacies to actively participate.
    Pharmacy, pharmacy, pharmacy,pharmnet.
    com.
    cn/news/yyzb/" target="_blank"> purchasing,pharmnet.
    com.
    cn/news/yyzb/" target="_blank"> purchasing, purchasing
     
      Union accelerate the pace of procurement involving varieties slashed prices
      Union accelerate the pace of procurement involving varieties slashed prices
     
      A few days ago, a "Notice of the Qinghai Provincial Medical Security Bureau Office on Filling in Data Related to the Centralized Procurement of Drugs by Xinjiang's Leading Organization of the Inter-provincial Alliance" circulated in the industry, requiring relevant data to be completed before April 12.
     
      According to the information in the form, Qinghai's participation in Xinjiang-led coalition sampling may involve 10 varieties, including: amoxicillin and clavulanate potassium, aspirin, sodium valproate, etc.
    , and there are many large clinical varieties.
     
      According to data from Meinenet, in 2019, the terminal sales of amoxicillin clavulanate potassium in urban public hospitals , county-level public hospitals, urban community centers, and township health centers in China exceeded 6 billion yuan, an increase of 6.
    88% year-on-year.
    Aspirin is the only internal pain reliever with sales of more than 1 billion yuan.
    In recent years, the sales of this product in the terminals of public medical institutions in China have continued to rise, breaking through 2 billion yuan in 2017 and rising to 2.
    4 billion yuan in 2019.
    Aspirin was included in last year's procurement in Shandong Province, and finally selected from the aspirin enteric-coated tablets in Yongning, Jinan.
    Each box of 100 tablets dropped to 0.
    58 yuan, and the price of a single tablet exceeded 6%.
    Hospital hospital hospital
     
      Up to now, together with the "2+4" alliance led by Xinjiang, seven inter-provincial alliances have emerged across the country, namely: the 11 provincial alliances led by Shaanxi; the five provincial alliances led by Chongqing; and the "six provinces and two districts" led by Sichuan Alliance; the 11-province alliance led by Guangdong; the Beijing-Tianjin-Hebei "3+N" alliance, and the "Yangtze River Delta Alliance" that has not yet announced the official procurement documents.
     
      The scale of the alliance's procurement and price reduction cannot be underestimated, and its influence is constantly increasing.
    The first batch of "six provinces and two districts" included 11 varieties in the first batch of inter-provincial alliances.
    The average price of selected drugs fell by 58.
    05%, with the largest decrease of 91.
    69%.
    The prices of many selected injections fell to the floor price.
    A few days ago, the Beijing-Tianjin-Hebei "3+N" alliance has announced the results of the joint procurement of coronary dilatation balloon medical consumables.
    The price of coronary dilatation balloons has dropped from an average price of 3401 yuan to 319 yuan, which is the same as in 2020.
    The average price of the same product of the enterprise is reduced by 90%.
    It is foreseeable that in 2021, Union procurement will bloom all over the country, and the quantity-harvested varieties will usher in a new round of price cuts.
     
      
      
      (Note: The form is circulated in the industry, and the official release shall prevail)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.